Identifying pancreatic cancer patients for targeted treatment: The challenges and limitations of the current selection process and vision for the future

Shayna L. Showalter, Sarah Charles, Justin Belin, Joseph Cozzitorto, Peter Einstein, Nathan G. Richards, Patricia K. Sauter, Eugene P. Kennedy, Agnes Witkiewicz, Jonathan R. Brody, Charles J. Yeo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Recent preclinical data have demonstrated that pancreatic adenocarcinoma (PDA) cells with defects in the Fanconi anemia/BRCA2 pathway are hypersensitive to interstrand crosslinking agents. The challenge is to efficiently identify patients who will benefit from these therapies. Patients were chosen for this study by evaluating personal history, ethnic background and family history of pancreatic malignancy. Molecular assays were performed on tissue samples. Patient A developed PDA in the context of a known BRCA2 frameshift mutation (2157delG), suspected because of her personal and multigenerational family history of breast cancer. She was treated with surgical resection, and targeted chemotherapy. Patient A continues to be disease free 32 months after her diagnosis and treatment. Patient B developed PDA in the context of a strong family history of PDA and Ashkenazi Jewish heritage. Genetic analysis on critical DNA repair genes revealed no alterations. This patient did not receive a tailored treatment regimen. This study highlights the challenge of treating PDA patients and selecting those eligible for targeted therapy. The current targeted treatment options for PDA are reviewed. A new multidisciplinary approach for stratifying PDA patients for promising targeted adjuvant therapy and familial risk counseling is proposed.

Original languageEnglish (US)
Pages (from-to)273-284
Number of pages12
JournalExpert Opinion on Drug Delivery
Volume7
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Pancreatic Neoplasms
Therapeutics
Fanconi Anemia
Frameshift Mutation
DNA Repair
Counseling
Adenocarcinoma
Breast Neoplasms
Drug Therapy
Genes
Neoplasms

Keywords

  • BRCA2
  • Familial pancreatic cancer
  • Fanconi anemia
  • Interstrand crosslinking agents
  • Pancreatic ductal adenocarcinoma
  • PARP inhibitors

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Identifying pancreatic cancer patients for targeted treatment : The challenges and limitations of the current selection process and vision for the future. / Showalter, Shayna L.; Charles, Sarah; Belin, Justin; Cozzitorto, Joseph; Einstein, Peter; Richards, Nathan G.; Sauter, Patricia K.; Kennedy, Eugene P.; Witkiewicz, Agnes; Brody, Jonathan R.; Yeo, Charles J.

In: Expert Opinion on Drug Delivery, Vol. 7, No. 3, 03.2010, p. 273-284.

Research output: Contribution to journalArticle

Showalter, SL, Charles, S, Belin, J, Cozzitorto, J, Einstein, P, Richards, NG, Sauter, PK, Kennedy, EP, Witkiewicz, A, Brody, JR & Yeo, CJ 2010, 'Identifying pancreatic cancer patients for targeted treatment: The challenges and limitations of the current selection process and vision for the future', Expert Opinion on Drug Delivery, vol. 7, no. 3, pp. 273-284. https://doi.org/10.1517/17425240903544462
Showalter, Shayna L. ; Charles, Sarah ; Belin, Justin ; Cozzitorto, Joseph ; Einstein, Peter ; Richards, Nathan G. ; Sauter, Patricia K. ; Kennedy, Eugene P. ; Witkiewicz, Agnes ; Brody, Jonathan R. ; Yeo, Charles J. / Identifying pancreatic cancer patients for targeted treatment : The challenges and limitations of the current selection process and vision for the future. In: Expert Opinion on Drug Delivery. 2010 ; Vol. 7, No. 3. pp. 273-284.
@article{8bdc2e2effbd4865a03cb81e9a43e4b4,
title = "Identifying pancreatic cancer patients for targeted treatment: The challenges and limitations of the current selection process and vision for the future",
abstract = "Recent preclinical data have demonstrated that pancreatic adenocarcinoma (PDA) cells with defects in the Fanconi anemia/BRCA2 pathway are hypersensitive to interstrand crosslinking agents. The challenge is to efficiently identify patients who will benefit from these therapies. Patients were chosen for this study by evaluating personal history, ethnic background and family history of pancreatic malignancy. Molecular assays were performed on tissue samples. Patient A developed PDA in the context of a known BRCA2 frameshift mutation (2157delG), suspected because of her personal and multigenerational family history of breast cancer. She was treated with surgical resection, and targeted chemotherapy. Patient A continues to be disease free 32 months after her diagnosis and treatment. Patient B developed PDA in the context of a strong family history of PDA and Ashkenazi Jewish heritage. Genetic analysis on critical DNA repair genes revealed no alterations. This patient did not receive a tailored treatment regimen. This study highlights the challenge of treating PDA patients and selecting those eligible for targeted therapy. The current targeted treatment options for PDA are reviewed. A new multidisciplinary approach for stratifying PDA patients for promising targeted adjuvant therapy and familial risk counseling is proposed.",
keywords = "BRCA2, Familial pancreatic cancer, Fanconi anemia, Interstrand crosslinking agents, Pancreatic ductal adenocarcinoma, PARP inhibitors",
author = "Showalter, {Shayna L.} and Sarah Charles and Justin Belin and Joseph Cozzitorto and Peter Einstein and Richards, {Nathan G.} and Sauter, {Patricia K.} and Kennedy, {Eugene P.} and Agnes Witkiewicz and Brody, {Jonathan R.} and Yeo, {Charles J.}",
year = "2010",
month = "3",
doi = "10.1517/17425240903544462",
language = "English (US)",
volume = "7",
pages = "273--284",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Identifying pancreatic cancer patients for targeted treatment

T2 - The challenges and limitations of the current selection process and vision for the future

AU - Showalter, Shayna L.

AU - Charles, Sarah

AU - Belin, Justin

AU - Cozzitorto, Joseph

AU - Einstein, Peter

AU - Richards, Nathan G.

AU - Sauter, Patricia K.

AU - Kennedy, Eugene P.

AU - Witkiewicz, Agnes

AU - Brody, Jonathan R.

AU - Yeo, Charles J.

PY - 2010/3

Y1 - 2010/3

N2 - Recent preclinical data have demonstrated that pancreatic adenocarcinoma (PDA) cells with defects in the Fanconi anemia/BRCA2 pathway are hypersensitive to interstrand crosslinking agents. The challenge is to efficiently identify patients who will benefit from these therapies. Patients were chosen for this study by evaluating personal history, ethnic background and family history of pancreatic malignancy. Molecular assays were performed on tissue samples. Patient A developed PDA in the context of a known BRCA2 frameshift mutation (2157delG), suspected because of her personal and multigenerational family history of breast cancer. She was treated with surgical resection, and targeted chemotherapy. Patient A continues to be disease free 32 months after her diagnosis and treatment. Patient B developed PDA in the context of a strong family history of PDA and Ashkenazi Jewish heritage. Genetic analysis on critical DNA repair genes revealed no alterations. This patient did not receive a tailored treatment regimen. This study highlights the challenge of treating PDA patients and selecting those eligible for targeted therapy. The current targeted treatment options for PDA are reviewed. A new multidisciplinary approach for stratifying PDA patients for promising targeted adjuvant therapy and familial risk counseling is proposed.

AB - Recent preclinical data have demonstrated that pancreatic adenocarcinoma (PDA) cells with defects in the Fanconi anemia/BRCA2 pathway are hypersensitive to interstrand crosslinking agents. The challenge is to efficiently identify patients who will benefit from these therapies. Patients were chosen for this study by evaluating personal history, ethnic background and family history of pancreatic malignancy. Molecular assays were performed on tissue samples. Patient A developed PDA in the context of a known BRCA2 frameshift mutation (2157delG), suspected because of her personal and multigenerational family history of breast cancer. She was treated with surgical resection, and targeted chemotherapy. Patient A continues to be disease free 32 months after her diagnosis and treatment. Patient B developed PDA in the context of a strong family history of PDA and Ashkenazi Jewish heritage. Genetic analysis on critical DNA repair genes revealed no alterations. This patient did not receive a tailored treatment regimen. This study highlights the challenge of treating PDA patients and selecting those eligible for targeted therapy. The current targeted treatment options for PDA are reviewed. A new multidisciplinary approach for stratifying PDA patients for promising targeted adjuvant therapy and familial risk counseling is proposed.

KW - BRCA2

KW - Familial pancreatic cancer

KW - Fanconi anemia

KW - Interstrand crosslinking agents

KW - Pancreatic ductal adenocarcinoma

KW - PARP inhibitors

UR - http://www.scopus.com/inward/record.url?scp=77749283334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749283334&partnerID=8YFLogxK

U2 - 10.1517/17425240903544462

DO - 10.1517/17425240903544462

M3 - Article

C2 - 20201734

AN - SCOPUS:77749283334

VL - 7

SP - 273

EP - 284

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 3

ER -